Ceftriaxone for Parkinson’s
On March 25, 2016, at a public discussion about new advances in the study of dementia and neurodegenerative diseases, professor Ho Ying-rui of the Department of Psychology at the Chungshan University in Taichung city, Taiwan, announced that the commonly used antibiotic called ceftriaxone to treat meningitis can suppress neuroinflammation in the substantia nigra in the brain and slow down dementia due to neurodegeneration in the dentate gyrus of the hippocampus.
Apparently, the ability of ceftriaxone to penetrate tissue and the cerebrospinal fluid to treat infection in the central nervous system also enables it to suppress neuroinflammation in the substantia nigra in the brain.
According to professor Ho Ying-rui, the findings would be applicable in treating dementia due to Parkinson’s disease.
The professor and his research and development team spent five years studying the effects of ceftriaxone.